Brief: Elevai Biosciences highlights Past Positive Preclinical Data Showing Potential Of El-32, A Dual Myostatin & Activin-A Blocker, For The Treatment Of Obesity
21/10/2024 13:16
Oct 21 (Reuters) - Elevai Labs Inc ELAB.O :
* ELEVAI BIOSCIENCES, A SUBSIDIARY OF ELEVAI LABS INC.,
HIGHLIGHTS
PAST POSITIVE PRECLINICAL DATA SHOWING POTENTIAL OF EL-32, A
DUAL MYOSTATIN & ACTIVIN-A BLOCKER, FOR THE TREATMENT OF OBESITY
* ELEVAI: EL-32 PRECLINICAL RESULTS SHOWED STATISTICALLY
SIGNIFICANT INCREASES IN GRIP STRENGTH, MOTOR FUNCTION & BODY
COMPOSITION IN AGED MOUSE MODEL
* ELEVAI: TO CONDUCT ADDITIONAL ANIMAL STUDIES TO ADVANCE
EL-32
TOWARDS IND APPLICATION
Source text for Eikon: ID:nGNX5gcf1H
Further company coverage: ELAB.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on PMGC Holdings
See all newsBrief: PMGC Holdings Signs Non-Binding Letter Of Intent To Acquire Majority Stake In US-Based Precision Machining Manufacturing Company Serving Aerospace, Space, Defense, And Semiconductor Markets
Brief: PMGC Holdings Offers $7.8 Million In Common Stock To Streeterville Capital
NASDAQ RESUMED AT 12:33 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:28 PM
NASDAQ RESUMED AT 09:46 AM